Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment

Steroids

Volumn 78, Issue 6, 2013, Pages 538-541

  Grubisha, Melanie J ^a   Defranco, Donald B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Estrogen receptor beta; Prostate cancer; Reactive oxygen species; Transforming growth factor beta; Tumor microenvironment

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR BETA;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONFERENCE PAPER; EPITHELIUM CELL; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; MOLECULAR INTERACTION; OXIDATIVE STRESS; PARACRINE SIGNALING; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ENDOCRINE SYSTEM; ESTROGEN RECEPTOR BETA; HUMANS; MALE; OXIDATION-REDUCTION; PARACRINE COMMUNICATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84876680123     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2013.01.005     Document Type: Conference Paper

References (46)

1. Z. Culig, A. Hobisch, M.V. Cronauer, C. Radmayr, J. Trapman, and A. Hittmair Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor Cancer Res 54 1994 5474 5478
2. D. Gioeli, S.B. Ficarro, J.J. Kwiek, D. Aaronson, M. Hancock, and A.D. Catling Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites J Biol Chem 277 2002 29304 29314
3. M. Pollak, W. Beamer, and J.C. Zhang Insulin-like growth factors and prostate cancer Cancer Metastasis Rev 17 1998 383 390
4. A. Wolk, C.S. Mantzoros, S.O. Andersson, R. Bergstrom, L.B. Signorello, and P. Lagiou Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study J Natl Cancer Inst 90 1998 911 915
5. Z.X. Zhou, M.V. Lane, J.A. Kemppainen, F.S. French, and E.M. Wilson Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability Mol Endocrinol 9 1995 208 218
6. V. Reebye, A. Frilling, N.A. Habib, and P.J. Mintz Intracellular adaptor molecules and AR signalling in the tumour microenvironment Cell Signal 23 2011 1017 1021
7. R.L. Bare, and F.M. Torti Endocrine therapy of prostate cancer Cancer Treat Res 94 1998 69 87
8. S.H. Fluchter, R. Weiser, and C. Gamper The role of hormonal treatment in prostate cancer Recent Results Cancer Res 175 2007 211 237
9. G. Mezo, M. Manea, I. Szabi, B. Vincze, and M. Kovacs New derivatives of GnRH as potential anticancer therapeutic agents Curr Med Chem 15 2008 2366 2379
10. C. Cai, and S. Balk Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy Endocr Relat Cancer 18 2011 R175 182
11. G. Attard, J. Richards, and J.S. de Bono New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Clin Cancer Res 17 2011 1649 1657
12. Y. Niu, S. Altuwaijri, K.P. Lai, C.T. Wu, W.A. Ricke, and E.M. Messing Androgen receptor is a tumor suppressor and proliferator in prostate cancer Proc Natl Acad Sci USA 105 2008 12182 12187
13. K.E. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol Metab 21 2010 315 324
14. S.J. Ellem, J.F. Schmitt, J.S. Pedersen, M. Frydenberg, and G.P. Risbridger Local aromatase expression in human prostate is altered in malignancy J Clin Endocrinol Metab 89 2004 2434 2441
15. G.P. Risbridger, S.J. Ellem, and S.J. McPherson Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling J Mol Endocrinol 39 2007 183 188
16. S.J. McPherson, H. Wang, M.E. Jones, J. Pedersen, T.P. Iismaa, and N. Wreford Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland Endocrinology 142 2001 2458 2467
17. J.J. Bianco, S.J. McPherson, H. Wang, G.S. Prins, and G.P. Risbridger Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life Am J Pathol 168 2006 1869 1878
18. M.J. Linja, K.J. Savinainen, T.L. Tammela, J.J. Isola, and T. Visakorpi Expression of ERalpha and ERbeta in prostate cancer Prostate 55 2003 180 186
19. G. Pelletier Expression of steroidogenic enzymes and sex-steroid receptors in human prostate Best Pract Res Clin Endocrinol Metab 22 2008 223 228
20. C.H. Adlercreutz, B.R. Goldin, S.L. Gorbach, K.A. Hockerstedt, S. Watanabe, and E.K. Hamalainen Soybean phytoestrogen intake and cancer risk J Nutr 125 1995 757S 770S
21. H. Adlercreutz, W. Mazur, P. Bartels, V. Elomaa, S. Watanabe, and K. Wahala Phytoestrogens and prostate disease J Nutr 130 2000 658S 659S
22. B. Kumar, S. Koul, L. Khandrika, R.B. Meacham, and H.K. Koul Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype Cancer Res 68 2008 1777 1785
23. M.J. Grubisha, M.E. Cifuentes, S.R. Hammes, and D.B. Defranco A local paracrine and endocrine network involving TGFbeta, Cox-2, ROS, and estrogen receptor beta influences reactive stromal cell regulation of prostate cancer cell motility Mol Endocrinol 26 2012 940 954
24. C. Yau, and C.C. Benz Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers Breast Cancer Res 10 2008 R61
25. R.M. Whittal, C.C. Benz, G. Scott, J. Semyonov, A.L. Burlingame, and M.A. Baldwin Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding Biochemistry 39 2000 8406 8417
26. C. Atsriku, G.K. Scott, C.C. Benz, and M.A. Baldwin Reactivity of zinc finger cysteines: chemical modifications within labile zinc fingers in estrogen receptor J Am Soc Mass Spectrom 16 2005 2017 2026
27. X. Liang, B. Lu, G.K. Scott, C.H. Chang, M.A. Baldwin, and C.C. Benz Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer Mol Cell Endocrinol 146 1998 151 161
28. G. Andriole, N. Bruchovsky, L.W. Chung, A.M. Matsumoto, R. Rittmaster, and C. Roehrborn Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia J Urol 172 2004 1399 1403
29. L.P. Nacusi, and D.J. Tindall Targeting 5alpha-reductase for prostate cancer prevention and treatment Nat Rev Urol 8 2011 378 384
30. R.S. Swerdloff, and C. Wang Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent Baillieres Clin Endocrinol Metab 12 1998 501 506
31. D. Dondi, M. Piccolella, A. Biserni, S. Della Torre, B. Ramachandran, and A. Locatelli Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta,17beta-diol Endocr Relat Cancer 17 2010 731 742
32. V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, and A. Maggi The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype Cancer Res 65 2005 5445 5453
33. P. Mak, I. Leav, B. Pursell, D. Bae, X. Yang, and C.A. Taglienti ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading Cancer Cell 17 2010 319 332
34. Q. Ji, L. Chang, D. VanDenBerg, F.Z. Stanczyk, and A. Stolz Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism Prostate 54 2003 275 289
35. J. Hofland, W.M. van Weerden, N.F. Dits, J. Steenbergen, G.J. van Leenders, and G. Jenster Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Res 70 2010 1256 1264
36. J.Y. Park, J.P. Tanner, T.A. Sellers, Y. Huang, C.K. Stevens, and N. Dossett Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk Urology 70 2007 374 379
37. P. Brozic, S. Turk, T.L. Rizner, and S. Gobec Inhibitors of aldo-keto reductases AKR1C1-AKR1C4 Curr Med Chem 18 2011 2554 2565
38. M. Guarino, B. Rubino, and G. Ballabio The role of epithelial-mesenchymal transition in cancer pathology Pathology 39 2007 305 318
39. C. Thomas, and J.A. Gustafsson The different roles of ER subtypes in cancer biology and therapy Nat Rev Cancer 11 2011 597 608
40. A. Kirschenbaum, X. Liu, S. Yao, and A.C. Levine The role of cyclooxygenase-2 in prostate cancer Urology 58 2001 127 131
41. E. Richardsen, R.D. Uglehus, J. Due, C. Busch, and L.T. Busund COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67 Cancer Epidemiol 34 2010 316 322
42. C.S. Williams, M. Tsujii, J. Reese, S.K. Dey, and R.N. DuBois Host cyclooxygenase-2 modulates carcinoma growth J Clin Invest 105 2000 1589 1594
43. C. Bucher, P. Jordan, V. Nickeleit, J. Torhorst, and M.J. Mihatsch Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin Clin Nephrol 51 1999 67 72
44. A.E. Norrish, R.T. Jackson, and C.U. McRae Non-steroidal anti-inflammatory drugs and prostate cancer progression Int J Cancer 77 1998 511 515
45. K. Saijo, J.G. Collier, A.C. Li, J.A. Katzenellenbogen, and C.K. Glass An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation Cell 145 2011 584 595
46. A. Mizokami, E. Koh, H. Fujita, Y. Maeda, M. Egawa, and K. Koshida The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor Cancer Res 64 2004 765 771